KEYCURE PHARMA LIMITED and SIRIUS 10 LTD join Altair Science cap table
Published
Altair Science Limited, a Wembley-based pharmaceutical firm founded in 2023, has seen two new investors join its cap table according to its latest confirmation statement (period ending 18 June 2026). The most significant change involves the entry of KEYCURE PHARMA LIMITED and SIRIUS 10 LTD, which have each acquired 25 ordinary shares.
KEYCURE PHARMA LIMITED is also a shareholder in MOLECULE PHARMA LIMITED. These new entries coincide with a reduction in holdings for the company's existing shareholders. R&V CONSULTANCY LTD and SIRIUS 28 LTD, which both previously held 50 ordinary shares, have decreased their respective stakes. Each entity now retains 25 ordinary shares. This redistribution of equity results in a cap table where four entities now hold equal stakes of 25 shares each.
Altair Science Limited focuses on drug development and commercialization through partnerships with research institutions and healthcare providers. The simultaneous entry of two new investors and the reduction of existing stakes may signal a recent private investment activity.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| New shareholder | KEYCURE PHARMA LIMITED | 25 | — | ORDINARY 25 |
| New shareholder | SIRIUS 10 LTD | 25 | — | ORDINARY 25 |
| Decreased | R&V CONSULTANCY LTD | 25 | -50% | ORDINARY 25 |
| Decreased | SIRIUS 28 LTD | 25 | -50% | ORDINARY 25 |
Current shareholders (4)
| Shareholder | Total shares | Share classes |
|---|---|---|
| SIRIUS 28 LTD | 25 | ORDINARY 25 |
| R&V CONSULTANCY LTD | 25 | ORDINARY 25 |
| SIRIUS 10 LTD | 25 | ORDINARY 25 |
| KEYCURE PHARMA LIMITED | 25 | ORDINARY 25 |
Contact the editorial team at [email protected]